Per Trollund Pedersen
Overview
Explore the profile of Per Trollund Pedersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nielsen L, Mercieca-Bebber R, Moller S, Redder L, Jarden M, Andersen C, et al.
Qual Life Res
. 2024 Jun;
33(9):2387-2400.
PMID: 38879861
Purpose: Non-response (NR) to patient-reported outcome (PRO) questionnaires may cause bias if not handled appropriately. Collecting reasons for NR is recommended, but how reasons for NR are related to missing...
2.
Harslof M, Chanchiri I, Silkjaer T, Frolund U, Teodorescu E, Nielsen K, et al.
EJHaem
. 2024 Apr;
5(2):316-324.
PMID: 38633122
Lenalidomide maintenance (LM) has shown benefit in progression-free survival (PFS) and overall survival (OS) in clinical trials. LM is the recommended standard of care in patients with newly diagnosed multiple...
3.
Al-Mashhadi A, Jakobsen L, Brown P, Gang A, Thorsteinsson A, Rasoul K, et al.
Br J Haematol
. 2023 Nov;
204(3):839-848.
PMID: 38009548
Outcome data of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) beyond the second line are scarce outside of clinical trials. Novel therapies in the R/R setting have been...
4.
Jonasson E, Antulov R, Pedersen P, Sejbaek T
Front Neurol
. 2023 May;
14:1098930.
PMID: 37213905
This paper demonstrates a case of progressive multifocal leukoencephalopathy (PML) in a patient with multiple myeloma (MM) treated with nine different MM therapies. This case report contributes to the already...
5.
Bertelsen L, Borty Nielsen L, Christensen H, Bogsted M, Gregersen H, Schou Pedersen R, et al.
Eur J Haematol
. 2022 Nov;
110(3):289-295.
PMID: 36413106
Background: The aetiology of multiple myeloma (MM) is unknown but various environmental exposures are suspected as risk factors. We present the first paper analysing the geographical distribution of MM in...
6.
Jakobsen L, Ovlisen A, Severinsen M, Baech J, Kragholm K, Glimelius I, et al.
Blood Cancer J
. 2022 Jan;
12(1):16.
PMID: 35087026
For most patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), R-CHOP immunochemotherapy leads to complete remission and 60-70% of patients remain progression-free after 5 years. Given a median age...
7.
Szabo A, Klausen T, Abildgaard N, Gregersen H, Silkjaer T, Pedersen P, et al.
Blood Cancer J
. 2021 Apr;
11(4):70.
PMID: 33828079
No abstract available.
8.
Clausen M, Maurer M, Ulrichsen S, Larsen T, Himmelstrup B, Ronnov-Jessen D, et al.
Clin Epidemiol
. 2019 Dec;
11:987-996.
PMID: 31814771
Background: Hemoglobin (Hgb) concentration at diagnosis is associated with outcome in cancer. In a recently reported simplified 3-factor prognostic score in Hodgkin lymphoma, Hgb, along with age and clinical stage,...
9.
Nielsen L, King M, Moller S, Jarden M, Andersen C, Frederiksen H, et al.
Qual Life Res
. 2019 Sep;
29(2):335-346.
PMID: 31549365
Purpose: The quality of patient-reported outcome (PRO) data can be compromised by non-response (NR) to scheduled questionnaires, particularly if reasons for NR are related to health problems, which may lead...
10.
Jakobsen L, Biccler J, de Nully Brown P, Jorgensen J, Josefsson P, Bjorn Poulsen C, et al.
Leuk Lymphoma
. 2019 May;
60(11):2798-2801.
PMID: 31057011
No abstract available.